IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY
IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY
复制标题
预测卵巢癌化疗反应的体外克隆发生分析
DOI：
10.1016/s0140-6736(80)90340-2
复制
发表时间：
1980
期刊：
影响因子：
--
通讯作者：
T. Moon
中科院分区：
文献类型：
--
作者：
D. Alberts;H. S. Chen;B. Soehnlen;S. Salmon;E. Surwit;L. Young;T. Moon
对 40 名晚期卵巢癌患者进行了 95 项抗癌药物临床试验，这些患者接受了体外软琼脂人类肿瘤干细胞药物敏感性测定。在 95 项临床试验中，21 名患者中有 13 名对体外预测有效的药物产生临床反应，而在体外预测耐药性的 74 名患者中，有 73 名对治疗没有反应。 2 名患者获得了 1 个月和 12 个月以上的完全缓解，11 名患者获得了中位持续 4 个月的部分缓解。体外耐药性的预测准确率为 99%。在经过广泛预处理的卵巢癌患者中，经过证实的体外疗效的药物达到了 62% 的完全或部分缓解率，这些患者不太可能对凭经验选择的二级药物产生反应。人类肿瘤干细胞检测将卵巢肿瘤集落形成单位培养在两层琼脂培养系统中，并结合药物敏感性或耐药性测试，可有效用于为卵巢癌患者规划合适的化疗方案。
95 clinical trials of anticancer drugs were done in 40 patients with advanced ovarian cancer who had undergone an in-vitro soft-agar human tumour stem-cell assay for drug sensitivity. In the 95 clinical trials, 13 of 21 patients responded clinically to drugs predicted to be effective in vitro, while in 73 of 74 instances in which drug resistance had been predicted in vitro there was no response to treatment. 2 patients achieved a complete remission of 1 and 12+months and 11 had partial remissions lasting a median of four months. Prediction of in-vitro resistance was 99% accurate. The 62% complete or partial remission rate to agents with proven in-vitro efficacy was achieved in extensively pretreated ovarian cancer patients who were unlikely to respond to empirically chosen secondary agents. The human tumour stem-cell assay, in which ovarian tumour colony-forming units are grown in a two-layer agar-culture system incorporating tests for drug sensitivity or resistance, can be effectively used to plan a suitable chemotherapy regimen for ovarian cancer patients.